VXRT VAXART INC Expansion Plans 8-K Filing 2025 - Product Expansion On May 27, 2025, Vaxart, Inc. announced the dosing of the first patient in its Phase 2b clinical trial for an oral COVID-19 vaccine, which involves 10,000 participants. This marks a significant step in its vaccine development.Get access to all SEC 8-K filings of the VAXART INC